Trending News

Stock market
#AstraZeneca #Business #Cancer research #Lung cancer #Oncology #Trial data

AstraZeneca stock value falls by 8%

Shares in AstraZeneca fell by 6% on July 3 when the company published the first results from its Phase III trial for datopotamab deruxtecan (Dato-DXd) and continued to fall throughout the day, though there was some recovery on July 4. It was reported that the therapy demonstrated statistically significant improvement… Read More

#Business & Investment #News #Trending News

#BioMarin Pharmaceuticals #Cell and gene therapy #FDA #Gene therapy #Haemophilia

One-time gene therapy for haemophilia A gets FDA green light

The US Food and Drug Administration (FDA) has approved the first gene therapy for adults with severe haemophilia A. BioMarin’s Roctavian (valoctocogene roxaparvovec-rvox) has been approved for the treatment of adults with severe haemophilia A (congenital factor VIII (FVIII) deficiency with FVIII activity < 1 IU/dL) without antibodies to adeno-associated… Read More

#News #Regulatory #Trending News

Approval stamp
#AAV #Advanced Therapy Medicinal Products (ATMPs) #Cell and gene therapy #Gene therapy #Genetics / genomics #Muscular dystrophy #Sarepta Therapeutics

FDA approves first gene therapy for Duchenne muscular dystrophy

Sarepta Therapeutics’ Elevidys has become the first gene therapy for Duchenne muscular dystrophy (DMD) to gain marketing authorisation in the US. The Food and Drug Administration (FDA) has granted accelerated approval to Elevidys (delandistrogene moxeparvovec-rokl), an adeno-associated virus (AAV) based gene therapy for the treatment of DMD. It is approved… Read More

#News #Regulatory #Trending News

Respiratory syncytial virus
#FDA #GSK #Immunology / Virology & Vaccines #Pfizer #Respiratory syncytial virus

GSK faces RSV vaccine threat from rival Pfizer  

An FDA approval for Pfizer’s Abrysvo respiratory syncytial virus (RSV) vaccine is likely to threaten GSK’s current hold on the market, according to GlobalData.  GSK received approval by the European Commision (EC) for its vaccine Arexvy, which targets the prevention of lower respiratory tract infections (LRTI) caused by RSV in… Read More

#News #Regulatory #Trending News

Cancer cells
#American Society of Clinical Oncology #Breast cancer #Cancer research #HER2 #Oncology #The College of American Pathologists

Updates to HER2 testing guidelines reduces confusion 

The College of American Pathologists (CAP) and American Society of Clinical Oncology (ASCO) have reaffirmed the Human Epidermal Growth Factor Receptor 2 (HER2) Breast Cancer Testing Guidelines, reducing confusion over terminology for reporting HER2 results.  The recent clinical trial for metastatic breast cancer patients (DESTINY-Breast04) found that a treatment traditionally… Read More

#Cancer Research #News #Regulatory #Trending News

Cancer cell
#Cancer research #Chemotherapy #Drug development #National Institute for Health and Care Excellence (NICE) #Regulatory

Positive NICE recommendation for BRCAm ovarian cancer 

AstraZeneca UK announced that Lynparza (olaparib) is recommended by the National Institute for Health and Care Excellence (NICE) for maintenance treatment of BRCA-mutated relapsed, platinum-sensitive, high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer in adults who have had two or more courses of platinum-based chemotherapy.  BRCA1 and BRCA2 are… Read More

#Editor's Choice #News #Regulatory #Trending News

Antibodies attack cancer cell
#ASCO #Cancer research #Clinical trials #Events #Oncology

Four breakthroughs in cancer research revealed at ASCO 2023

Ground-breaking data from several key cancer trials were announced at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. ADAURA Phase III trial The trial assessed Tagrisso (osimertinib) as an adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated… Read More

#Cancer Research #News #Trending News

Breast cancer
#ASCO #Breast cancer #Cancer research #Novartis #Oncology #Phase III trial

Drug reduced the risk of breast cancer recurrence by 25%

Positive primary endpoint data from Novartis’ pivotal Phase III NATALEE trial has been presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. Data showed that Kisqali (ribociclib) plus endocrine therapy (ET), compared to ET alone, lowered the risk of cancer recurrence by 25.2%… Read More

#Cancer Research #News #Trending News

Laboratory research
#Antibody #ASCO #Cancer research #Clinical trials #Immunotherapy #Janssen #Oncology #T cell activation

Janssen updates ASCO 2023 on oncology pipeline

Janssen has presented new data from across its oncology pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Talquetamab Talquetamab is an investigational GPRC5D-directed bispecific antibody currently in clinical development. Updated results from the Phase II MonumenTAL-1 study show that… Read More

#Cancer Research #News #Trending News

Vaccine
#FDA #Immunology / Virology & Vaccines #Pfizer #Phase III trial #Respiratory syncytial virus

FDA approves first vaccine for respiratory syncytial virus

The US Food and Drug Administration (FDA) has approved Pfizer’s bivalent respiratory syncytial virus (RSV) prefusion F (RSVpreF) vaccine Abrysvo in individuals 60 years and older. Abrysvo is unadjuvanted and composed of two preF proteins selected to optimise protection against RSV A and B strains and… Read More

#News #Trending News

Non-small cell lung cancer
#American Society of Clinical Oncology #ASCO #AstraZeneca #Cancer research #Lung cancer #Oncology #Phase III trial

Lung cancer pill reduced risk of death by more than half

Positive results from the ADAURA Phase III trial showed AstraZeneca’s Tagrisso (osimertinib) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared to placebo. The trial assessed osimertinib as an adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor… Read More

#Cancer Research #News #Trending News

US Food and Drug Administration
#FDA #Gene therapy #Krystal Biotech #Rare disease

FDA approves first gene therapy for rare skin disorder

The US Food and Drug Administration has approved Krystal Biotech’s Vyjuvek, a herpes-simplex virus type 1 (HSV-1) vector-based gene therapy, for the treatment of dystrophic epidermolysis bullosa (DEB). It is approved for treating wounds in patients six months of age and older with mutation(s) in the collagen type VII alpha… Read More

#News #Regulatory #Trending News

Lipid nanoparticle mRNA vaccine
#Advanced Therapies #Cell and gene therapy #Moderna #mRNA #Phase II trial #Rare disease

Positive initial data on first mRNA therapy for propionic acidemia

Moderna has reported encouraging interim data from its Phase I/II trial of mRNA-3927, an mRNA therapy for rare metabolic disorder propionic acidemia (PA). The data was presented at the 2023 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting. The ongoing global Phase… Read More

#News #Trending News

DNA vector
#Cell and gene therapy #FDA #Gene therapy #Muscular dystrophy #Sarepta Therapeutics

FDA committee supports gene therapy for muscular dystrophy

The US Food and Drug Administration (FDA) Cellular, Tissue and Gene Therapies Advisory Committee (CTGTAC) have voted eight to six in favour of a new gene therapy for Duchenne muscular dystrophy. The vote supports the accelerated approval of Sarepta Therapeutics’ SRP-9001 (delandistrogene moxeparvovec) for the treatment of ambulatory patients with… Read More

#News #Regulatory #Trending News